About this data
Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.
Antihyperglycemic medication
- Company
- Eli Lilly and Company
- Mechanism
- Mechanism not yet reported
- Route
- Route not yet reported
- Recruiting trials
- None currently listed
Efficacy results: Not yet reported
No recruiting studies currently listed
See all studies for this drugData source: ClinicalTrials.gov · trial data as of Nov 13, 2026
Trial details
-
Completed NCT NCT00548808
A Study for Type 2 Diabetic Patients
Not yet reported Eli Lilly and Company 426 participants Est. completion 2009-08 25 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT01029288
Impact of Decision Aids to Enhance Shared Decision Making for Diabetes
Not yet reported Mayo Clinic 110 participants Est. completion 2013-01 5 sitesOther conditions: DiabetesView official trial listing → -
Completed NCT NCT01033773
Stop Emergency Room Visits for Hyperglycemia Project - District of Columbia (DC)
Not yet reported Medstar Health Research Institute 86 participants Est. completion 2009-01 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT01357135
An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)
Merck Sharp & Dohme LLC 3453 participants Est. completion 2013-08-31Type 2 diabetesView official trial listing → -
Completed NCT NCT01427660
iDecide.Decido: Diabetes Medication Decision Support Study
Not yet reported University of Michigan 190 participants Est. completion 2013-10 1 siteOther conditions: Diabetes, Type 2View official trial listing → -
Completed NCT NCT01584232
A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus
Not yet reported Eli Lilly and Company 361 participants Est. completion 2013-07 15 sites Stand-aloneType 2 diabetesView official trial listing → -
Withdrawn NCT NCT02106364
A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus
Not yet reported Eli Lilly and Company Est. completion 2016-06 10 sites Stand-aloneType 2 diabetesView official trial listing → -
Status unknown NCT NCT02198846
A Study to Compare Insulin Pump With Conventional Treatment in Type 2 Diabetes
Not yet reported Konkuk University Medical Center 140 participants Est. completion 2015-03 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT02302716
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
Not yet reported Eli Lilly and Company 493 participants Est. completion 2016-07 44 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT03338010
A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus
Not yet reported Eli Lilly and Company 536 participants Est. completion 2020-03-18 32 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT03861039
A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes
Not yet reported Eli Lilly and Company 443 participants Est. completion 2021-02-16 34 sites Added to GLP-1Type 2 diabetesView official trial listing → -
Completed NCT NCT04521049
Tubular Markers in Response to Saxagliptin Therapy
Not yet reported Beni-Suef University 80 participants Est. completion 2020-04-01 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT04809220
A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes
Not yet reported Eli Lilly and Company 591 participants Est. completion 2023-04-26 44 sites Added to GLP-1Type 2 diabetes Other conditions: Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases, Hypoglycemic AgentsView official trial listing → -
Completed NCT NCT05036421
Effect of Glucuronosyltransferase (UGT) Genetic Variation on Pharmacokinetics of Empagliflozin
Not yet reported Ain Shams University 18 participants Est. completion 2022-05-20 1 site Stand-aloneOther conditions: Pharmacogenomic, PharmacokineticsView official trial listing → -
Active, not recruiting NCT NCT05433584
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
Not yet reported Eli Lilly and Company 794 participants Est. completion 2027-11 90 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT06236672
Impact of GLP-1 RAs Compared to Basal Insulin Start in Patients Living With Type 2 Diabetes and Chronic Kidney Disease
LMC Diabetes & Endocrinology Ltd. 348 participants Est. completion 2023-11-29 1 siteType 2 diabetesChronic kidney diseaseView official trial listing → -
Enrolling by invitation NCT NCT06846138
Enhancing the Efficacy and Tolerability of Metformin by add-on Polyherbal Formulation: a Gut Microbiome Study
Not yet reported Pauls Stradins Clinical University Hospital 66 participants Est. completion 2026-12-01 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT07424430
Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes
LMC Diabetes & Endocrinology Ltd. 3392 participants Est. completion 2026-09-28 1 siteType 2 diabetes Other conditions: Diabetes (DM), Obesity (Disorder)View official trial listing → -
Active, not recruiting NCT NCT07502495
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets
Not yet reported Biomea Fusion Inc. 64 participants Est. completion 2027-09 18 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT07787754
The Effect of Sea Buckthorn Extract in Patients With Type 1 Diabetes
Not yet reported The First Affiliated Hospital of Guangzhou Medical University 30 participants Est. completion 2023-12-31 1 site Stand-aloneOther conditions: Type 1 DiabetesView official trial listing →
Efficacy history
Not yet reported.
Safety
Not yet reported.
Sources
Related On The Pen coverage
No related coverage yet.
This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.